Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients

被引：1

作者：

Bonazzi, Norma ^{[1
]}

Fortunati, Emilia ^{[2
]}

Zanoni, Lucia ^{[2
]}

Argalia, Giulia ^{[1
]}

Calabro, Diletta ^{[1
]}

Tabacchi, Elena ^{[2
]}

Allegri, Vincenzo ^{[2
]}

Campana, Davide ^{[3
,4
]}

Andrini, Elisa ^{[3
,4
]}

Lamberti, Giuseppe ^{[3
,4
]}

Di Franco, Martina ^{[1
]}

Casadei, Riccardo ^{[5
,6
]}

Ricci, Claudio ^{[5
,6
]}

Mosconi, Cristina ^{[4
,7
]}

Fanti, Stefano ^{[1
,2
]}

Ambrosini, Valentina ^{[1
,2
]}

机构：

[1] Univ Bologna, Nucl Med, Alma Mater Studiorum, I-40126 Bologna, Italy

[2] Azienda Osped Univ Bologna, Nucl Med, IRCCS, I-40138 Bologna, Italy

[3] Azienda Osped Univ Bologna, Med Oncol, IRCCS, I-40138 Bologna, Italy

[4] Univ Bologna, Dept Med & Surg Sci DIMEC, Alma Mater Studiorum, I-40126 Bologna, Italy

[5] Univ Bologna, Dept Internal Med & Surg DIMEC, Alma Mater Studiorum, I-40126 Bologna, Italy

[6] Azienda Osped Univ Bologna, Div Pancreat Surg, IRCCS, I-40138 Bologna, Italy

[7] Azienda Osped Univ Bologna, Dept Radiol, IRCCS, I-40138 Bologna, Italy

来源：

CANCERS | 2024年 / 16卷 / 04期

关键词：

PET/CT; 68Ga]Ga-DOTANOC; neuroendocrine neoplasms; neuroendocrine tumors; indications; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS; RECEPTOR RADIONUCLIDE THERAPY; GUIDELINE; NEOPLASMS; GA-68;

D O I：

10.3390/cancers16040701

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Neuroendocrine neoplasms' (NENs) rarity and heterogeneity represent a clinical challenge. Somatostatin receptor (SST) positron emission tomography/computed tomography (PET/CT) availability and different reimbursement policies across countries account for its heterogenous employment on a single-case basis. The aim of this study was to prospectively collect data of the real-life use of and indications for [68Ga-DOTA0-1NaI3]octreotide ([68Ga]Ga-DOTANOC) PET/CT in a prospective 5-year electronic archive at a single center. Overall, more than 2000 scans were included. This systematic data collection in a high-volume diagnostic center represents a reliable cohort reflecting the trends of [68Ga]Ga-DOTANOC PET/CT use across different clinical indications and primary tumor sites.Abstract The recent introduction of novel treatments for advanced neuroendocrine tumors (NETs) and the well-established impact of clinical case discussion within dedicated multidisciplinary teams indicates the need to promote the centralization of rare diseases, such as NENs (neuroendocrine neoplasms). Data on the real-life use of and indications for [68Ga]Ga-DOTANOC PET/CT were collected from a prospective monocentric 5-year electronic archive including consecutive patients with confirmed and suspected NETs (September 2017 to May 2022). Overall, 2082 [68Ga]Ga-DOTANOC PET/CT scans (1685 confirmed NETs, 397 suspected NETs) were performed in 1537 patients. A high positivity rate was observed across different clinical settings (approximately 70%). Approximately 910/2082 scans were requested by the local oncology ward (851 confirmed NETs, 59 suspected NETs). The following observations were found: (i) the detection rate across all indications was 73.2% (higher for staging, peptide receptor radioligand therapy (PRRT) selection, and treatment response assessment); (ii) in suspected NETs, PET was more often positive when based on radiological findings. This systematic data collection in a high-volume diagnostic center represents a reliable cohort reflecting the global trends in the use of [68Ga]Ga-DOTANOC PET/CT for different clinical indications and primary tumor sites, but prompts the need for further multicenter data sharing in such a rare and slowly progressive disease setting.

引用

页数：13